Omega-3 fatty acids' supplementation in Alzheimer's disease: A systematic review
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Alzheimer's disease (AD) is a neurodegeneration disorder characterized by progressive impairments of memory, language, reasoning, and other cognitive functions. Evidence suggests that omega-3 fatty acids may act as a possible protection factor in AD. OBJECTIVE: To evaluate the results available in the literature involving omega-3 fatty acids supplementation and its effect on cognitive function in AD patients. METHODS: A systematic review of MEDLINE (from PubMed), Excerpta Medica Database, and Cochrane Library databases was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Inclusion criteria consisted in original intervention studies, controlled by placebo, that assessed the impact of supplementation or dietary intake of omega-3 fatty acids on cognitive function, in humans with AD, without limitation for prime date of publication. RESULTS: Initial search resulted in 361 articles. Seven studies fully met the inclusion criteria. Most studies did not find statistically significant results for the omega-3 fatty acids supplementation compared to placebo, and those who show some benefit do it only in a few cognitive assessment scales. However, the effects of omega-3 fatty acids appear to be most effectively demonstrated in patients with very mild AD. CONCLUSION: The effects of omega-3 fatty acids supplementation in mild AD corroborate epidemiological observational studies showing that omega-3 fatty acids may be beneficial in disease onset, when there is slight impairment of brain function. Although some studies have shown changes in scales of cognitive function in more severe cases, they are not enough to support omega-3 fatty acids supplementation in the treatment of AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite the multiple purported clinical benefits, the published evidence for OM-3 dietary supplements is generally insufficient, inconsistent, or negative.”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [35]
In the citing paper
“In terms of brain health, a systematic review of seven clinical studies of OM-3 dietary supplements for Alzheimer’s disease (AD) found that cognitive improvement was observed in some cases, particularly in very mild AD; however, the collective evidence was insufficient to support OM-3s in the treatment of AD [35].”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [35]
In the citing paper
“Despite the multiple purported benefits, systematic reviews and meta-analyses have found the clinical evidence for OM-3 dietary supplements in these health conditions to be insufficient, inconsistent, or negative [34–39].”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [35]
In the citing paper
“In terms of brain health, a systematic review of seven clinical studies of OM-3 dietary supplements for Alzheimer’s disease (AD) found that cognitive improvement was observed in some cases, particularly in very mild AD; however, the collective evidence was insufficient to support OM-3s in the treatment of AD [35].”
From Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review (2020) · cites this paper as [35]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Forecasting the global burden of Alzheimer's disease
Brookmeyer, R., Johnson, E., Ziegler‐Graham, K., & Arrighi, H. M. (2007) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.04.381 · Cited by 3,370
Epidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Midwife-led continuity models versus other models of care for childbearing women
Sandall, J., Soltani, H., Gates, S., Shennan, A., & Devane, D. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004667.pub3 · Cited by 1,226
An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Consumption of Fish and n-3 Fatty Acids and Risk of Incident Alzheimer Disease
Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., Bennett, D. A., Wilson, R. S., Aggarwal, N., & Schneider, J. (2003) · Archives of Neurology · doi:10.1001/archneur.60.7.940 · Cited by 1,135
Research works printed but not linked: 2
- Masters CL, 2016, Nat Rev Dis Prim, 1, 1
- 2016, Cochrane Database Syst Rev, 4, 1
Cited by
Djuricic, I., & Calder, P. C. (2021) · Nutrients · doi:10.3390/nu13072421 · Cited by 1,015
“8 g EPA + DHA daily identified a slower rate of cognitive decline in those receiving omega-3 fatty acids [134], while a systematic review reached the conclusion that the most beneficial effect of EPA and DHA supplementation in Alzheimer’s patients can be expected in the early stage of the disease [135].”
ResultApoptosis and Oxidative Stress in Neurodegenerative Diseases
Radi, E., Formichi, P., Battisti, C., & Federico, A. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132738 · Cited by 630
Type 3 Diabetes and Its Role Implications in Alzheimer’s Disease
Nguyen, T. T., Ta, Q. T. H., Nguyen, T. K. O., Nguyen, T. T. D., & Van Giau, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093165 · Cited by 393
“The essential role of omega-3 fatty acids in brain development and maintenance has been well recognized, particularly in the past ten years, yet only recently “have their effects on brain aging been explored” [82].”
BackgroundPistollato, F., Iglesias, R. C., Ruiz, R., Aparicio, S., Crespo, J., Lopez, L. D., Manna, P. P., Giampieri, F., & Battino, M. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.012 · Cited by 247
Troesch, B., Eggersdorfer, M., Laviano, A., Rolland, Y., Smith, A. D., Warnke, I., Weimann, A., & Calder, P. C. (2020) · Nutrients · doi:10.3390/nu12092555 · Cited by 226
“A recent systematic review also reached the conclusion that the most beneficial effect of EPA and DHA supplementation in Alzheimer’s patients can be expected in the early stage of the disease [72].”
Metadata
- Authors
- Canhada, S., Castro, K., Perry, I. S., & Luft, V. C.
- Affiliations
- Universidade Federal do Rio Grande do Sul (BR)
- Food and Nutrition Research Centre (CESAN), Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
- Corresponding author
- Canhada, Scheine
- Venue
- Nutritional Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2017-05-03
- Volume
- 21
- Issue
- 8
- Pages
- 529-538
- ISSN
- 1028-415X (ISSN-L)
- 1476-8305
- OpenAlex
- W2611431983
- Cited by
- 156
- References
- 35
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 23 · 2023: 15 · 2022: 20 · 2021: 17 · 2020: 27 · 2019: 14 · 2018: 7 · 2017: 4
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nutritional Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- omega-3 fatty acids, Alzheimer's disease, dietary supplementation, cognitive function, neurodegeneration, mild Alzheimer's disease, cognitive impairment
- MeSH terms
- Diet, Healthy, Alzheimer Disease, Animals, Anti-Inflammatory Agents, Non-Steroidal, Cognition, Fish Oils, Fishes, Humans, Patient Compliance, Severity of Illness Index, Reproducibility of Results, Fatty Acids, Omega-3, Seafood, Neuroprotective Agents, Nootropic Agents, Controlled Clinical Trials as Topic, Evidence-Based Medicine, Dietary Supplements
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Omega-3 fatty acids' supplementation in Alzheimer's disease: A systematic review. https://app.cochat.ai/papers/10.1080/1028415x.2017.1321813
- The paper
- Canhada, S., Castro, K., Perry, I. S., & Luft, V. C. (2018). Omega-3 fatty acids' supplementation in Alzheimer's disease: A systematic review. Nutritional Neuroscience. https://doi.org/10.1080/1028415x.2017.1321813
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.